Lipoprotein(a): A Promising Marker for Residual Cardiovascular Risk Assessment

Lipoprotein(a): A Promising Marker for Residual Cardiovascular Risk Assessment

Atherosclerotic cardiovascular diseases (CVD) are still the leading cause of morbidity and mortality worldwide, although optimal medical therapy has been prescribed for primary and secondary preventions. Residual cardiovascular risk for some population groups is still considerably high although target low density lipoprotein-cholesterol (LDL-C) level has been achieved. During the past few decad...

Adiponectin: a promising marker for cardiovascular disease.

Obesity is a major risk factor for coronary heart disease (CHD). Obese persons have an 1.5to 2.0-fold increased risk for CHD, and between 15% and 20% of all cases of CHD can be attributed to overweight and obesity (1 ). Although hypertension, dyslipidemia, insulin resistance, and type 2 diabetes are core components of the metabolic syndrome and are probably key elements in the causal pathway fr...

Lipoprotein (a), an independent cardiovascular risk marker

Epidemiological and genetic studies have identified elevated levels of lipoprotein (a) ((Lp(a)) as a causal and independent risk factor for cardiovascular diseases (CVD). The Lp(a)-induced increased risk of CVD may be mediated by both its proatherogenic and prothrombotic mechanisms. Several guidelines recommend screening of Lp(a) level; however, there are few treatment options for the managemen...

Apolipoproteins for cardiovascular risk assessment.

Atherogenic Index of Plasma (AIP): A marker of cardiovascular disease

Background: Cardiovascular disease (CVD) is the cause of one third of deaths worldwide and this will progress because of increasing CVD's risk factors. The most basic task of dealing with the epidemic of CVD is primary prevention of risk factors. As Atherogenic Index of Plasma (AIP) is a strong marker to predict the risk of atherosclerosis and coronary heart disease, we assessed the correlat...